Genocea Biosciences Inc. Stock
Your prediction
Genocea Biosciences Inc. Stock
Genocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Pros and Cons of Genocea Biosciences Inc. in the next few years
Pros
Cons
Performance of Genocea Biosciences Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - | - | - | - | - |
| Evolus Inc | 2.620% | -0.077% | -12.697% | -31.421% | -4.367% | -41.438% | -40.434% |
| Heron Therapeutics Inc. | -1.610% | 1.641% | 16.685% | -72.205% | -61.077% | -71.285% | -95.688% |
| Rhythm Pharmaceuticals | -1.050% | -2.162% | -8.122% | 20.667% | -3.209% | 315.138% | 666.949% |
Comments
